Macrophage inflammatory protein-1α expression plasmid enhances DNA vaccine-induced immune responses against HSV-2

Immunology and Cell Biology

Volumn 83, Issue 6, 2005, Pages 626-631

  Shao, Wenai ^a   Li, Xiaomian ^b   Li, Mei ^b   Shi, Liying ^b   Qin, Yu ^b   Li, Kangsheng ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

DNA vaccine; HSV 2; MIP 1

Indexed keywords

CYTOKINE; DNA VACCINE; GLYCOPROTEIN D; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PLASMID; STATISTICAL ANALYSIS; SURVIVAL RATE; TH1 CELL; TH2 CELL; VACCINATION; VIRUS STRAIN;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FEMALE; HERPESVIRUS 2, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; PLASMIDS; SPLEEN; SURVIVAL RATE; TH1 CELLS; TH2 CELLS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

ANIMALIA; HUMAN HERPESVIRUS 2;

EID: 30544452889     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01380.x     Document Type: Article

References (24)

1. Corey L. Increasing prevalence of HSV-II points to need for more effective prevention strategies. Herpes 2002; 9: 3.
2. Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000; 283: 791-4.
3. Stanberry LR, Cunning AL, Mindel A. Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 2000; 30: 549-66.
4. Gurunathan S, Klinman DM, Seder RA. DNA vaccine: immunology, application and optimization. Annu. Rev. Immunol. 2000; 18: 927-74.
5. Carr MW, Roth SJ, Luther E et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl Acad. Sci. USA. 1994; 91: 3652-6.
6. Karpus WJ, Lukacs NM, Kennedy KJ et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol. 1997; 158: 4129-36.
7. Lukacs NW, Chensue SW, Karpus WJ et al. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am. J. Pathol. 1997; 150: 1861-8.
8. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol. Today 1994; 15: 127-33.
9. Taub DD, Turcovski-Corrales SM, Key ML et al. Chemokines and T lymphocyte activation. I. Beta chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 1996; 156: 2095-103.
10. Eo SK, Lee SJ, Chun SJ et al. Modulation of immunity against Herpes Simplex Virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J. Virol. 2001; 75: 569-78.
11. Sin JI, Kim JJ, Pachuk C et al. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4+ T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 2000; 74: 1173-80.
12. Sin JI, Kim JJ, Arnold RL et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 type CD4+ T cell mediated protective immunity against HSV-2 challenge. J. Immunol 1999; 162: 2912-21.
13. Sin JI, Sung JH, Suh YS et al. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of co-injection with a granulocyte, macrophage-colony stimulating factor gene. Vaccine 1997; 15: 1827-33.
14. Parr EL, Bozzola JJ, Parr MB. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. J. Reprod. Immunol. 1998; 38: 15-30.
15. He Q, Mitchell A, Morcol T et al. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin. Diagn. Lab. Immunol. 2002; 9: 1021-4.
16. Gillgrass AE, Ashkar AA, Rosenthal KL, Kaushic C et al. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 2003; 77: 9845-51.
17. Kwant A, Rosenthal KL. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004; 22: 3098-104.
18. Jeong IS, Jong JK, Kenneth EU et al. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur. J. Immunol. 1999; 28: 3530-40.
19. Smith JR, Thackray AM, Bujdoso R. Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 2001; 102: 352-8.
20. Tanigawa M, Bigger JE, Kanter MY et al. Natural killer cells prevent direct anterior-to-posterior spread of herpes simplex virus type 1 in the eye. Invest. Opthalmol. Vis. Sci. 2000; 41: 352-8.
21. Sin JI, Ayyavoo V, Boyer J et al. Protective immune correlates can segregate by vaccine type in a murine herpes model system. Int. Immunol. 1999; 11: 1763-73.
22. Kim JJ, Nottingham LK, Sin JI et al. CD8 positive T-cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Invest. 1998; 102: 1112-24.
23. Sallusto F, Lenig D, Mackay CR et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 1998; 187: 875-83.
24. Tumpey TM, Cheng H, Yan XT et al. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J. Leukoc. Biol. 1998; 63: 486-92.